Bridgeway Capital Management’s LeMaitre Vascular LMAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-7,600
Closed -$403K 1298
2021
Q3
$403K Buy
+7,600
New +$428K 0.01% 1094
2021
Q2
Sell
-17,200
Closed -$839K 1367
2021
Q1
$839K Hold
17,200
0.02% 922
2020
Q4
$697K Buy
+17,200
New +$615K 0.01% 840
2016
Q4
Sell
-40,000
Closed -$794K 1442
2016
Q3
$794K Sell
40,000
-10,200
-20% -$178K 0.01% 895
2016
Q2
$716K Hold
50,200
0.01% 901
2016
Q1
$779K Hold
50,200
0.01% 870
2015
Q4
$866K Hold
50,200
0.02% 819
2015
Q3
$612K Hold
50,200
0.01% 940
2015
Q2
$605K Buy
50,200
+200
+0.4% +$1.97K 0.01% 979
2015
Q1
$419K Hold
50,000
0.01% 1161
2014
Q4
$383K Hold
50,000
0.01% 1159
2014
Q3
$344K Sell
50,000
-250
-0.5% -$1.87K 0.01% 1229
2014
Q2
$416K Hold
50,250
0.01% 1170
2014
Q1
$406K Hold
50,250
0.01% 1167
2013
Q4
$403K Buy
50,250
+250
+0.5% +$1.93K 0.01% 1131
2013
Q3
$335K Hold
50,000
0.01% 1190
2013
Q2
$327K Buy
+50,000
New +$315K 0.01% 1136

Other funds holding LMAT

Bridgeway Capital Management's LMAT Position: Q4 2021 in Review

Bridgeway Capital Management sold out of LeMaitre Vascular (LMAT) in Q4 2021, closing a stake of 7,600 shares — an estimated $403K sold.

Bridgeway Capital Management first reported a position in LMAT in Q2 2013 and held it in 17 quarters. The position peaked at $866K in Q4 2015. 183 funds tracked by Wall St. Rank hold LMAT as of Q4 2021.

  • Bridgeway Capital Management reported no remaining LeMaitre Vascular position as of Q4 2021 after selling out during the quarter.
  • Bridgeway Capital Management sold 7,600 LeMaitre Vascular shares in Q4 2021, an estimated $403K.
  • Bridgeway Capital Management first reported a position in LeMaitre Vascular in Q2 2013 and held it in 17 quarters.
  • Bridgeway Capital Management's LeMaitre Vascular position peaked at $866K in Q4 2015.
  • 183 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q4 2021.

Based on Bridgeway Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.